Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)

v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
 1 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Number of Reportable Segments | segment   1  
Fixed asset impairment charges   $ 0 $ 0
Uninsured cash balances   9,123,000  
Cancer treatment research award   2,000,000.0  
Reduction in research and development   $ 1,759,000  
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration] Costs and Expenses    
Cancer treatment research award through the National Cancer Institute (NCI)      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Reduction in research and development     $ 697,000
Grant received $ 1,980,000    
Minimum      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Property and equipment useful lives   3 years  
Share-based compensation expiration period   12 months  
Maximum      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Property and equipment useful lives   10 years  
Share-based compensation expiration period   3 years  
Leasehold improvements      
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Property and equipment useful lives   64 months